Odyssey Therapeutics, Inc. (ODTX) Stock

About Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.

Odyssey Therapeutics, Inc. is led by CEO Gary D. Glick, employs 100 people, headquartered in US, publicly traded since 2026.

Odyssey Therapeutics, Inc. (ODTX) stock trades at $21.94 with a market capitalization of $663.25M. The stock is valued at a price-to-earnings (P/E) ratio of -4.07, price-to-book of -1.24, price-to-sales of 222.87. Over the past 52 weeks the stock has ranged between $15.10 and $22.26, and currently trades 1.4% below its 52-week high.

On profitability, Odyssey Therapeutics, Inc. generates a return on equity (ROE) of 30.44% — well above the market average, a sign of a high-quality business, return on capital employed of -66.23%, an operating margin of -5366.67%, a net profit margin of -4966.67%.

Official website: odysseytx.com